The emergence of extensively drug-resistant tuberculosis: A global health crisis requiring new interventions: Part I: The origins and nature of the problem

Clinical and Translational Science

Volumn 1, Issue 3, 2008, Pages 249-254

  Ellner, Jerrold J ^a  

^a RUTGERS NEW JERSEY MEDICAL SCHOOL   (United States)

Author keywords

Drug resistant tuberculosis; Extensively drug resistant tuberculosis; Multidrug resistant tuberculosis; Tuberculosis

Indexed keywords

AMIKACIN; AMINOSALICYLIC ACID; AMOXICILLIN PLUS CLAVULANIC ACID; CAPREOMYCIN; CIPROFLOXACIN; CLARITHROMYCIN; CLOFAZIMINE; CYCLOSERINE; ETHAMBUTOL; ETHIONAMIDE; ISONIAZID; KANAMYCIN; LEVOFLOXACIN; LINEZOLID; MOXIFLOXACIN; OFLOXACIN; PYRAZINAMIDE; QUINOLINE DERIVED ANTIINFECTIVE AGENT; RIFABUTIN; RIFAMPICIN; SPARFLOXACIN; STREPTOMYCIN; THIOACETAZONE;

ANTIBIOTIC SENSITIVITY; BACTERIAL STRAIN; BACTERIAL TRANSMISSION; EPIDEMIC; GENOTYPE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFECTION RATE; MIXED INFECTION; MULTIDRUG RESISTANCE; MYCOBACTERIUM BOVIS; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; PRIORITY JOURNAL; PROGNOSIS; PUBLIC HEALTH PROBLEM; REVIEW; SALVAGE THERAPY; TUBERCULOSIS; TUBERCULOSIS CONTROL;

EXTENSIVELY DRUG-RESISTANT TUBERCULOSIS; HUMANS; MICROBIAL SENSITIVITY TESTS; TREATMENT OUTCOME; WORLD HEALTH;

EID: 77953408365     PISSN: 17528054     EISSN: 17528062     Source Type: Journal    
DOI: 10.1111/j.1752-8062.2008.00060.x     Document Type: Review

References (55)

1. Canetti GJ. Changes in tuberculosis as seen by a pathologist. Am Rev Tuberc. 1959; 79 (5): 684-686.
2. Fox W, Wiener A, Mitchison DA, Selkon JB, Sutherland I. The prevalence of drug-resistant tubercle bacilli in untreated patients with pulmonary tuberculosis: A national survey, 1955-56. Tubercle. 1957; 38 (2): 71-84.
3. Mitchison DA. Development of streptomycin resistant strains of tubercle bacilli in pulmonary tuberculosis: Results of simultaneous sensitivity tests in liquid and on solid media. Thorax. 1950; 5 (2): 144-161.
4. Mitchison DA. Tubercle bacilli resistant to isoniazid; virulence and response to treatment with isoniazid in guinea-pigs. BMJ. 1954; 1 (4854): 128-130.
5. Iseman MD. Extensively drug-resistant Mycobacterium tuberculosis: Charles Darwin would understand. Clin Infect Dis. 2007; 45 (11): 1415-1416.
6. Teixeira L, Perkins MD, Johnson JL, et al. Infection and disease among household contacts of patients with multidrug-resistant tuberculosis. IntJ Tuberc Lung Dis. 2001; 5 (4): 321-328.
7. Zignol M, Hosseini MS, Wright A, Lambregts-van Weezenbeek C, Nunn P, Watt A, William BG, Dye C. Global incidence of multidrug-resistant tuberculosis. J Infect Dis. 2006; 194 (4): 479-485.
8. Singh JA, Upshur R, Padayatchi N. XDR-TB in South Africa: No time for denial or complacency. PLoSMed. 2007; 4 (1): E50.
9. Raviglione MC, Smith IM. XDR tuberculosis-implications for global public health. N Engl J Med. 2007; 356 (7): 656-659.
10. Chaisson RE, Martinson NA. Tuberculosis in Africa-combating an HIV-driven crisis. N Engl J Med. 2008; 358 (11): 1089-1092.
11. Shah N, Wright A, Drobniewski F. Extreme drug resistance in tuberculosis ("XDR-TB"): Globa survey of supranational reference laboratories for Mycobacterium tuberculosis with resistance to second line drugs. Int J Tuberc Lung Dis. 2005; 9 (Suppl 1): S77.
12. Emergence of Mycobacterium tuberculosis with extensive drug resistance to second-line drugs-wordwide, 2000-2004. MMWR Morb Mort WklyRep. 2006; 55 (11): 301-305. second-line drugs-wordwide, 2000-2004
13. Extensively drug resistant TB (XDR-TB): Recommendations for prevention and control. Wkly Epidemiol Rec. 2006; 81: 430-432.
14. Perdigao J, Macedo R, Joao I, Fernandes E, Brum L, Portugal I. Multidrug-resistant tuberculosis in Lisbon, Portugal: A molecular epidemiological perspective. Microb Drug Resist. 2008; 14 (2) 133-143.
15. Gandhi NR, Moll A, Sturm AW, Pawinski R, Govender T, Lalloo U, Zeller K, Andrews J, Friedland G. Extensively drug-resistant tuberculosis as a cause of death in patients co-infected with tuberculosis and HIV in a rural area of South Africa. Lancet. 2006; 368 (9547): 1575-1580.
16. Frieden TR, Sterling T, Pablos-Mendez A, Kilburn JO, Cauthen GM, Dooley SW. The emergence of drug-resistant tuberculosis in New York City. N Engl J Med. 1993; 328 (8): 521-526.
17. Hannan MM, Peres H, Maltez F, Hayward AC, Machado J, Morgado A, Proenca R, Nelson MR, Bico J, Young DB, Gazzard BS. Investigation and control of a large outbreak of multi-drug resistant tuberculosis at a central Lisbon hospital. J Hosp Infect. 2001; 47 (2): 91-97.
18. Punnotok J, Shaffer N, Naiwatanakul T, Pumprueg U, Subhannachart P, Ittiravivongs A, Chuchotthaworn C, Ponglertnapagorn P, Chantharojwong N, Young NL, Limpakarnjanarat K, Mastro TD. Human immunodeficiency virus-related tuberculosis and primary drug resistance in Bangkok, Thailand. Int J Tuberc Lung Dis. 2000; 4 (6): 537-543.
19. Ritacco V, Di Lonardo M, Reniero A, et al. Nosocomial spread of human immunodeficiency virus-related multidrug-resistant tuberculosis in Buenos Aires. J Infect Dis. 1997; 176 (3): 637-642.
20. Rullan JV, Herrera D, Cano R, Moreno V, Godoy P, Peiro EF, Castell J, Ibanez C, Ortega A, Agudo LS, Pozo F. Nosocomial transmission of multidrug-resistant Mycobacterium tuberculosis in Spain. Emerg Infect Dis. 1996; 2 (2): 125-129.
21. Sacks LV, Pendle S, Orlovic D, Blumberg L, Constantinou C. A comparison of outbreak- and nonoutbreak-related multidrug-resistant tuberculosis among human immunodeficiency virus-infected patients in a South African hospital. Clin Infect Dis. 1999; 29 (1): 96-101.
22. Campos PE, Suarez PG, Sanchez J, et al. Multidrug-resistant Mycobacterium tuberculosis in HIV-infected persons, Peru. Emerg Infect Dis. 2003; 9 (12): 1571-1578.
23. Daley CL, Small PM, Schecter GF, Schoolnik GK, McAdam RA, Jacobs WR, Hopewell PC. An outbreak of tuberculosis with accelerated progression among persons infected with the human immunodeficiency virus. An analysis using restriction-fragment-length polymorphisms. N Engl J Med. 1992; 326 (4): 231-235.
24. Joseph P, Severe P, Ferdinand S, Goh KS, Sola C, Haas DW, Johnson WD, Rastogi N, Pape JW, Fitzgerald DW. Multidrug-resistant tuberculosis at an HIV testing center in Haiti. AIDS. 2006; 20 (3): 415-418.
25. Koenig R. Drug-resistant tuberculosis. In South Africa, XDR TB and HIV prove a deadly combination. Science. 2008; 319 (5865): 894-897.
26. Kenyon TA, Mwasekaga MJ, Huebner R, Rumisha D, Binkin N, Maganu E. Low levels of drug resistance amidst rapidly increasing tuberculosis and human immunodeficiency virus co-epidemics in Botswana. IntJ Tuberc Lung Dis. 1999; 3 (1): 4-11.
27. Churchyard GJ, Corbett EL, Kleinschmidt I, Mulder D, De Cock KM. Drug-resistant tuberculosis in South African gold miners: Incidence and associated factors. Int J Tuberc Lung Dis. 2000; 4 (5): 433-440.
28. Wilkinson D, Pillay M, Davies GR, Sturm AW. Resistance to antituberculosis drugs in rura South Africa: Rates, patterns, risks, and transmission dynamics. Trans R Soc Trop Med Hyg. 1996; 90 (6): 692-695.
29. Andrews JR, Shah NS, Gandhi N, Moll T, Friedland G. Multidrug-resistant and extensively drug-resistant tuberculosis: Implications for the HIV epidemic and antiretroviral therapy rollout in South Africa. J Infect Dis. 2007; 196 (Suppl 3): S482--S490.
30. Jeon CY, Hwang SH, Min JH, Prevots DR, Goldfeder LC, Lee H, Eum SY, Jeon DS, Kang HS, Kim JH, Kim BJ, Kim DY, Holland SM, Park SK, Cho SN, Barry CE 3rd, Via LE. Extensively drug-resistant tuberculosis in South Korea: risk factors and treatment outcomes among patients at a tertiary referral hospital. Clin Infect Dis. 2008; 46 (1): 42-49.
31. Masjedi MR, Farnia P, Sorooch S, et al. Extensively drug-resistant tuberculosis: 2 years of surveillance in Iran. Clin Infect Dis. 2006; 43 (7): 841-847.
32. Dahle UR. Extensively drug resistant tuberculosis: Beware patients lost to follow-up. BMJ 2006; 333 (7570): 705.
33. Dahle UR, Eldholm V, Winje BA, Mannsaker T, Heldal E. Impact of immigration on the molecular epidemiology of Mycobacterium tuberculosis in a low-incidence country. Am J Respir Crit Care Med. 2007; 176 (9): 930-935.
34. Banerjee R, Allen J, Westenhouse J, Oh P, Elms W, Desmond E, Nitta A, Royce S, Flood J. Extensively drug-resistant tuberculosis in California, 1993-2006. Clin Infect Dis. 2008; 47 (4): 450-457.
35. Pillay M, Sturm AW. Evolution of the extensively drug-resistant F15/LAM4/ KZN strain of Mycobacterium tuberculosis in KwaZulu-Natal, South Africa. Clin Infect Dis. 2007; 45 (11) 1409-1414.
36. Han LL, Sloutsky A, Canales R, Naroditskaya V, Shin SS, Seung KJ, Timperi R, Becerra MC. Acquisition of drug resistance in multidrug-resistant/Wyco/pacfe/vum tuberculosis during directly observed empiric retreatment with standardized regimens. Int J Tuberc Lung Dis. 2005; 9 (7): 818-821.
37. Samper S, Martin C. Spread of extensively drug resistant tuberculosis. Emerg Infect Dis. 2007; 13 (4): 647-648.
38. Guerrero A, Cobo J, Fortun J, et al. Nosocomial transmission of Mycobacterium bovis resistant to 11 drugs in people with advanced HIV-1 infection. Lancet. 1997; 350 (9093): 1738-1742.
39. Rivero A, Marquez M, Santos J, Pinedo A, Sanchez MA, Esteve A, Samper S, Martin C. High rate of tuberculosis reinfection during a nosocomial outbreak of multi-drug resistant tuberculosis caused by Mycobacterium bovis strain B. Clin Infect Dis. 2001; 32: 159-161.
40. Migliori GB, Lange C, Centis R, Sotgiu G, Mutterlein R, Hoffmann H, Kliiman K, De laco G, Lauria FN, Richardson MD, Spanevello A, Cirillo DM, TBNET Study Group. Resistance to second-line injectables and treatment outcomes in multidrug-resistant and extensively drug-resistant tuberculosis cases. Eur Respir J. 2008; 31 (6): 1155-1159.
41. Leimane V, Riekstina V, Holtz TH, Zarovska E, Skripconoka V, Thorpe L, Laserson K, Wells C. Clinical outcome of individualised treatment of multidrug-resistant tuberculosis in Latvia: A retrospective cohort study. Lancet. 2005; 365 (9456): 318-326.
42. Kwon YS, Kim YH, Suh GY, Ching MP, Kim H, Kwon OJ, Choi YS, Kim K, Kim J, Shim YM, Koh WJ. Treatment outcomes for HIV-uninfected patients with multidrug-resistant and extensively drug-resistant tuberculosis. Clin Infect Dis. 2008; 47 (4): 496-502.
43. Kim HR, Hwang SS, Kim HJ, Lee SM, Yoo CG, Kim YW, Han SK, Shim YS, Yim JJ. Impact of extensive drug resistance on treatment outcomes in non-HIV-infected patients with multidrug-resistant tuberculosis. Clin Infect Dis. 2007; 45 (10): 1290-1295.
44. Kim DH, Kim HJ, Park SK, Kong SJ, Kim YS, Kim TH, Kim EK, Lee KM, Lee SS, Park JS, Koh WJ, Lee CH, Kim JY, Shim TS. Treatment outcomes and long-term survival in patients with extensively drug-resistant tuberculosis. Am J Respir Crit Care Med. 2008.
45. Bonilla CA, Crossa A, Jave HO, Mitnick CD, Jamanca RB, Herrera C, Asencios L, Mendoza A, Bayona J, Zignol M, Jaramillo E. Management of extensively drug-resistant tuberculosis in Peru: Cure is possible. PLoS ONE. 2008; 3 (8): E2957.
46. Chan ED, Strand MJ, Iseman MD. Treatment outcomes in extensively resistant tuberculosis. N EnglJMed. 2008; 359 (6): 657-659.
47. Mitnick CD, Shin SS, Seung KJ, Rich ML, Atwood SS, Furin JJ, Fitzmaurice GM, Alcantara Vim FA, Appleton SC, Bayona JN, Bonilla CA, Chalco K, Choi S, Franke MF, Fraser HSF, Guerra D, Hurtado RM, Jazayeri D, Joseph K, Llaro K, Mestanza L, Mukherjee JS, Munoz M, Palacios E, Sanchez E, Sloutsky A, Becerra MC. Comprehensive treatment of extensively drug-resistant tuberculosis. N Engl J Med. 2008; 359 (6): 563-574.
48. Raviglione MC. Facing extensively drug-resistant tuberculosis - a hope and a challenge. N Engl J Med. 2008; 359 (6): 636-638.
49. Chan ED, Laurel V, Strand MJ, Chan JF, Huynh MN, Goble M, Iseman MD. Treatment and outcome analysis of 205 patients with multidrug-resistant tuberculosis. Am J Respir Crit Care Med. 2004; 169 (10): 1103-1109.
50. Jugheli L, Rigouts L, Shamputa IC, Bram de Rijk W, Portaels F. High levels of resistance to second-line anti-tuberculosis drugs among prisoners with pulmonary tuberculosis in Georgia. Int J Tuberc Lung Dis. 2008; 12 (5): 561-566.
51. Temple B, Ayakaka I, Ogwang S, Nabanjja H, Kayes S, Nakubulwa S, Worodria W, Levin J, Joloba M, Okwera A, Eisenach KD, McNerney R, Elliott AM, Smith PG, Mugerwa RD, Ellner JJ, Jones-Lopez, EC. Rate and amplification of drug resistance in previously-treated tuberculosis patients in Kampala, Uganda. Clin infect Dis. 2008; 47: 1126-1134.
52. Migliori GB, Lange C, Centis R, Sotgiu G, Mutterlein R, Hoffmann H, Kliiman K, De laco G, Lauria FN, Richardson MD, Spanevello A, Cirillo DM, and TBNET Study Group. Resistance to second-line injectables and treatment outcomes in multidrug-resistant and extensively drug-resistant tuberculosis cases. Eur Respir J. 2008; 31 (6): 1155-1159.
53. Frieden TR, Munsiff SS, Ahuja SD. Outcomes of multidrug-resistant tuberculosis treatment in HIV-positive patients in New York City, 1990-1997. Int J Tuberc Lung Dis. 2007; 11 (1): 116.
54. Condos R, Hadgiangelis N, Leibert E, Jacquette G, Harkin J, Rom WN. Case series report of a linezolid-containing regimen for extensively drug-resistant tuberculosis. Chest. 2008; 134 (1): 187-192.
55. von der Lippe B, Sandven P, Brubakk O. Efficacy and safety of linezolid in multidrug resistant tuberculosis (MDR-TB) - a report of ten cases. J Infect. 2006; 52 (2): 92-96.